|Bid||678.60 x 0|
|Ask||678.50 x 0|
|Day's Range||677.40 - 691.20|
|52 Week Range||441.50 - 742.20|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||40.63|
|Earnings Date||Jan 31, 2024|
|Forward Dividend & Yield||7.08 (1.03%)|
|Ex-Dividend Date||Aug 18, 2023|
|1y Target Est||715.28|
Subscribe to Yahoo Finance Plus to view Fair Value for NOVO-B.CO
Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.